Group 1 - The company, Rendu Biotech, has completed a change in registered capital, which is now set at RMB 400.69870 million [2] - The company has canceled its supervisory board and updated its articles of association [2] - Rendu Biotech has received a new business license from the Shanghai Municipal Market Supervision Administration [2]

证券代码：688193 证券简称：仁度生物 公告编号：2025-052 | 公司名称 | 上海仁度生物科技股份有限公司 | | --- | --- | | 统一社会信用代码 | 91310115662456111U | | 类型 | 股份有限公司(外商投资、上市) | | 法定代表人 | JINGLIANG JU | | 注册资本 | 人民币 万 4,006.9870 | | 成立日期 | 年 月 日 2007 06 13 | | 住所 | 上海市张江高科技园区东区瑞庆路 528 号 15 幢乙号 | | 经营范围 | 许可项目：第三类医疗器械经营；第三类医疗器械生产；第二类 | | | 医疗器械生产。(依法须经批准的项目，经相关部门批准后方可 | | | 开展经营活动，具体经营项目以相关部门批准文件或许可证件为 | 上海仁度生物科技股份有限公司 关于公司完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日、 ...

Core Points - The company has elected Ms. Cao Ruohua as an employee director during the recent employee representative meeting, with her term starting from the approval date until the end of the second board's term [1] - Ms. Cao was previously a non-employee director and her election does not change the overall composition of the board [1] - The board's structure remains compliant with relevant laws and regulations, ensuring that employee representatives and senior management do not exceed half of the total board members [1] Summary of Ms. Cao Ruohua's Profile - Ms. Cao Ruohua, born in July 1966, is a Taiwanese national with an educational background in economics from National Taiwan University and an MBA from the University of Chicago [2] - Her professional experience includes roles at Procter & Gamble, Milk International Holdings, and Kanglian Holdings, and she has been the Deputy General Manager of the company since November 2020 [2] - As of the announcement date, Ms. Cao directly holds 25,000 shares in the company and has indirect holdings through various asset management plans [2] Compliance and Eligibility - Ms. Cao meets all eligibility criteria to serve as a director, with no disqualifications under the Company Law of the People's Republic of China [3] - She has not faced any sanctions from the China Securities Regulatory Commission or been deemed unsuitable by stock exchanges [3] - There are no legal investigations or allegations against her that would affect her position [3]

Core Viewpoint - Rendu Biotech announced the election of Ms. Cao Ruohua as the employee director of the company during a recent meeting [1] Company Summary - Rendu Biotech held a meeting where the election of Ms. Cao Ruohua as the employee director was unanimously agreed upon [1]

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

证券代码：688193 证券简称：仁度生物 公告编号：2025-051 上海仁度生物科技股份有限公司 关于公司选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、修订后的《上 海仁度生物科技股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 上海仁度生物科技股份有限公司（以下简称"公司"）于近日召开职工代表大会选 举职工董事，经出席会议的全体职工代表讨论、表决，会议一致同意选举曹若华 女士为公司职工董事，任期自本次职工代表大会审议通过之日起至公司第二届董 事会任期届满之日止。 曹若华女士原为公司第二届董事会非职工董事，本次选举完成后，其变更为 公司第二届董事会职工董事，董事会构成人员不变。本次选举职工董事工作完成 后，公司第二届董事会中兼任公司高级管理人员职务以及由职工代表担任的董事， 总计未超过公司董事总数的 1/2，符合有关法律法规、规范性文件及《公司章程》 的规定。 曹若华女士个人简历详见附件。 特此公告。 上海仁度生物科技股份有限公司 董事 ...

Market Overview - The precision medicine sector experienced a decline of 1.61% on November 21, with Berry Genomics leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Key stocks in the precision medicine sector showed varied performance, with the following notable changes: - United Imaging Healthcare (688271) increased by 2.15% to a closing price of 133.50 [1] - Berry Genomics (000710) fell by 8.67% to a closing price of 11.59, with a trading volume of 233,200 shares and a turnover of 278 million [2] - WuXi AppTec (603259) decreased by 2.00% to a closing price of 91.80, with a significant trading volume of 346,800 shares and a turnover of 3.197 billion [1] Capital Flow - The precision medicine sector saw a net outflow of 678 million from institutional investors, while retail investors contributed a net inflow of 705 million [2] - The following stocks experienced notable capital flows: - New Open Source (300109) had a net inflow of 22.76 million from institutional investors [3] - ST Xiangxue (300147) faced a significant net outflow of 17.12 million from institutional investors [3]

Group 1 - The core viewpoint of the article is that Rendu Biotech announced its mid-year profit distribution plan for 2025, which includes a cash dividend of 0.15 yuan per share (tax included) [1] - The record date for the dividend is set for November 25, 2025, while the ex-dividend date and the date of cash dividend distribution are both scheduled for November 26, 2025 [1]

中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁 度生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在 科创板上市的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券法》《证 券发行上市保荐业务管理办法》《上海证券交易所上市公司自律监管指引第 7 号——回 购股份》等法律法规要求，对公司 2025 年中期利润分配所涉及的差异化分红进行了核 查，具体情况如下： 中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 差异化分红事项的核查意见 公司已于 2024 年 2 月 18 日召开第二届董事会第三次会议，审议通过了《关于以集 中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金不低于人民币 2,500 万元（含）且不超过人民币 5,000 万元（含），以集中竞价交易方式回购公司股份，回 购价格不超过人民币 53.31 元/股（含），本次回购股份将用于员工持股计划或股权激励。 回购期限为自公司董事会审议通过回购方案之日起不超过 6 个月。 一、本次差异化分红的原因 截至 2024 年 8 月 16 日，公司本次回购计划已实施完毕，已实际回购公 ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-050 上海仁度生物科技股份有限公司 2025年中期权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/11/25 | 2025/11/26 | 2025/11/26 | 一、 通过分配方案的决策程序 3. 差异化分红送转方案： （1）本次差异化分红送转方案根据公司 2024 年年度股东大会审议通过的《关 于提请股东大会授权董事会决定 2025 年中期利润分配的议案》及第二届董事会第 十四次会议审议通过的《关于公司 2025 年度中期利润分配预案的议案》，公司向 实施权益分派股权登记日登记的总股本扣减公司回购专用证券账户中的股份为基 数，每股派发现金红利 0.15 元（含税）。如在实施权益分派的股权登记日前因股份 回购等事项导致公司可参与分配股本发生变动的，维持每股分配比例不变，相应 调整现金分红总额。本次利润分配以权益分 ...